FDA Recalls Levothyroxine and Liothyronine Tablets Due to Content Uniformity Failures
Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient and poor manufacturing controls.
The agency’s classification
FDA (Drugs): Class I
Class I is a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 5/5 (Critical).
Highest-severity recall. The hazard can cause serious injury or death. Stop using the product now and follow the agency's instructions.
Our severity reasoning: The agency classification is FDA Class I, which per the rubric mandates a score of 5 (Critical) regardless of other factors.
Plain-English summary
The U.S. Food and Drug Administration (FDA) has issued a Class I recall for Levothyroxine and Liothyronine (Thyroid Tablets, USP), 1 & 1/2 grain (90 mg), 100-count bottles. The product is manufactured for Westminster Pharmaceuticals, LLC, and is available by prescription only. The recall covers specific lots with expiration dates ranging from July 31, 2019, to March 31, 2020.
The recall was initiated because the product was manufactured using an adulterated active pharmaceutical ingredient. Additionally, a lack of process controls and good manufacturing practices resulted in the finished product failing content uniformity specifications. This failure means the tablets may contain a strength that is more or less than what is labeled on the bottle.
The affected products were distributed nationwide in the USA and Puerto Rico. Patients who have been prescribed this medication should contact their healthcare provider for guidance on alternative treatments or to determine if they need to stop taking the recalled product.
The recalled product
- Product
- Levothyroxine and Liothyronine (Thyroid Tablets, USP), 1 & 1/2 grain (90 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmaceuticals, LLC, 154 Downing Street, Unit 1 & 2, Olive Branch, MS 38654, NDC 69367-157-04.
- Manufacturer
- Westminster Pharmaceuticals LLC
- Category
- Drug — Thyroid Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lot #: 15717VP-01
- 15717VP-02
- 15717VP-03
- Exp 7/31/2019
- 15717002
- Exp 12/31/2019
- 15718004
- Exp 3/31/2020.
Distribution
Part of a larger recall action
This product is one of 5 recalled by Westminster Pharmaceuticals LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same manufacturer · Westminster Pharmaceuticals LLC
See all →- HighMetoprolol tartrate 100 mg tablets exceed the nitrosamine daily intake level
FDA (Drugs) · 2025-08-20
- HighMetoprolol tartrate tablets recalled for nitrosamine above acceptable daily intake level
FDA (Drugs) · 2025-08-20
- SevereWestminster Irbesartan Tablets Recalled Due to NDEA Impurity Traces
FDA (Drugs) · 2018-12-19
- SevereWestminster Irbesartan Tablets Recalled Due to NDEA Impurity Traces
FDA (Drugs) · 2018-12-19
- SevereWestminster Irbesartan Tablets Recalled Due to NDEA Impurity
FDA (Drugs) · 2018-12-19
Same hazard · content uniformity
See all →- ModeratePreferred Pharmaceuticals Recalls Lidocaine Ointment Due to Content Uniformity Failures
FDA (Drugs) · 2026-10-14
- ModerateLupin Recalls Clobetasol Propionate Cream for Content Uniformity Failures
FDA (Drugs) · 2026-09-02
- HighOral contraceptive tablets recalled after failing content uniformity specifications
FDA (Drugs) · 2025-10-15
- HighCefixime Oral Suspension Recalled for Failed Content Uniformity Specifications
FDA (Drugs) · 2024-06-26
- SevereFDA Recalls Phenytoin Oral Suspension Due to Content Uniformity Failure
FDA (Drugs) · 2023-12-27
Similar recalls
- Moderate
- ModerateFDA Recalls Potentially Mislabeled Levothyroxine/Liothyronine Tablets
FDA (Drugs) · 2014-01-22
- HighLevothyroxine sodium tablets recalled for potency failures nationwide
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled for Potency Variation and Dosage Failures
FDA (Drugs) · 2024-12-18
- ModerateLiothyronine Sodium USP Recalled for Missing Stability Data
FDA (Drugs) · 2018-02-28
- ModerateMylan Recalls Subpotent Levothyroxine Sodium Tablets Due to Stability Testing Failures
FDA (Drugs) · 2014-02-19